Trafalgar International (GCAN) Non-Current Assets (2018 - 2024)
Trafalgar International (GCAN) posted Non-Current Assets of $417.0 for Q4 2024, down 74.99% on a QoQ basis from $1667.0 in Q3 2024, and down 92.3% year-over-year from $5417.0 in Q1 2024.
Powered by 
Analysis
Trafalgar International (GCAN) Non-Current Assets (2018 - 2024) Analysis & Trends
Trafalgar International has reported Non-Current Assets for 7 years, with the latest figure at $417.0 in Q4 2024.
- On a quarterly basis, Non-Current Assets fell 92.3% year-over-year to $417.0 in Q4 2024; TTM through Sep 2025 was $417.0, a 97.06% decrease from a year earlier, with the FY2024 full-year figure at $417.0, down 92.3% from the prior year.
- Non-Current Assets was $417.0 for Q4 2024 at Trafalgar International, down from $1667.0 in the prior quarter.
- The five-year high for Non-Current Assets was $24167.0 in Q1 2020, with the low at $417.0 in Q4 2024.
- Average Non-Current Assets over 5 years is $12292.0, with a median of $12292.0 recorded in 2022.
- The sharpest annual moves came in 2021 and 2024: Non-Current Assets fell 20.69% in 2021, then plunged 92.3% in 2024.
- Over 5 years, Non-Current Assets stood at $20417.0 in 2020, then slipped by 24.49% to $15417.0 in 2021, then sank by 32.43% to $10417.0 in 2022, then slumped by 48.0% to $5417.0 in 2023, then slumped by 92.3% to $417.0 in 2024.
- The last three Non-Current Assets figures came in at $417.0 (Q4 2024), $1667.0 (Q3 2024), and $2917.0 (Q2 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 141.29 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 101.45 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 125.00 Mn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 94.68 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 159.77 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 113.37 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 294.93 Mn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 1.85 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 3.74 Bn |
| 10 | Trafalgar International | 217,335.05 | 217,335.05 | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 417.00 |
| Sep 30, 2024 | 1,667.00 |
| Jun 30, 2024 | 2,917.00 |
| Mar 31, 2024 | 4,167.00 |
| Dec 31, 2023 | 5,417.00 |
| Sep 30, 2023 | 6,667.00 |
| Jun 30, 2023 | 7,917.00 |
| Mar 31, 2023 | 9,167.00 |
| Dec 31, 2022 | 10,417.00 |
| Sep 30, 2022 | 11,667.00 |
| Jun 30, 2022 | 12,917.00 |
| Mar 31, 2022 | 14,167.00 |
| Dec 31, 2021 | 15,417.00 |
| Sep 30, 2021 | 16,667.00 |
| Jun 30, 2021 | 17,917.00 |
| Mar 31, 2021 | 19,167.00 |
| Dec 31, 2020 | 20,417.00 |
| Sep 30, 2020 | 21,667.00 |
| Jun 30, 2020 | 22,917.00 |
| Mar 31, 2020 | 24,167.00 |